SpaceX vs. RKLB: Barclays Sees 58% Upside in One Space Stock
Barclays initiated coverage of SpaceX (SPCX) and Rocket Lab (RKLB) with Overweight ratings, seeing 58% and 24% upside respectively. ARK Investment Management praised Rocket Lab's Neutron rocket, comparing it to SpaceX's Falcon 9, and added $16.6M in RKLB shares. RKLB gained 1% premarket after a 5% drop, while SPCX also rose.
How this was made
The 30-second read
Why it matters
The upgrade provides a catalyst for short‑term buying, especially in pre‑market trading, while highlighting Rocket Lab's upcoming Neutron rocket as a growth driver.
Market read
Analyst initiation and price targets create immediate upside potential for Rocket Lab, with broader implications for the space launch sector.
What to watch
Potential delays in Neutron development and reliance on large contracts could temper upside.
Background
Barclays analyst Anthony Valentini initiated coverage of both Rocket Lab (RKLB) and SpaceX (SPCX) with Overweight ratings, setting new price targets.
Ticker impact
Barclays initiated coverage of Rocket Lab with an Overweight rating and a $85 price target, implying 24% upside.
likely upward pressure as traders price in the 24% upside target.
The new coverage and target are fresh information that can move the stock in pre‑market trading.
Market effects
Positive outlook for the U.S. aerospace and defense sector as analysts favor defense‑tech firms.
U.S. small‑cap space sector may see modest gains.
Limited to investors focused on space launch companies.
Counterpoint
SpaceX remains dominant; Rocket Lab's growth may be constrained by competition and limited launch cadence.
Key entities
- companyRocket Lab
U.S. aerospace firm developing the Neutron launch vehicle.
- financial_institutionBarclays
Analyst firm that issued the new ratings and price targets.
